Sutro Biopharma, Inc.
STRO
$0.9026
-$0.3974-30.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 73.81% | -66.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 73.81% | -66.86% | |||
| Cost of Revenue | -371.31% | 0.14% | |||
| Gross Profit | 442.08% | -47.57% | |||
| SG&A Expenses | -36.99% | 15.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.75% | 2.75% | |||
| Operating Income | 3.92% | -39.51% | |||
| Income Before Tax | -43.66% | -1.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -48.49% | -1.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -48.49% | -1.60% | |||
| EBIT | 3.92% | -39.51% | |||
| EBITDA | 4.13% | -41.00% | |||
| EPS Basic | -47.66% | -0.58% | |||
| Normalized Basic EPS | 3.86% | -35.88% | |||
| EPS Diluted | -47.66% | -0.58% | |||
| Normalized Diluted EPS | 3.86% | -35.88% | |||
| Average Basic Shares Outstanding | 0.57% | 1.01% | |||
| Average Diluted Shares Outstanding | 0.57% | 1.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||